Reversal of oral anticoagulation

Pharmacotherapy

Volumn 33, Issue 11, 2013, Pages 1199-1213

  Thigpen, Jonathan L ^a   Limdi, Nita A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

adverse drug reactions; anticoagulation; cardiology; patient safety; pharmacogenomics; pharmacology

Indexed keywords

ANTIDOTE; COFACT; DABIGATRAN; FRESH FROZEN PLASMA; HEMATOLOGIC AGENT; PROTHROMBIN COMPLEX; RECOMBINANT ACTIVATED FACTOR VII; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

BLEEDING; CLINICAL EFFECTIVENESS; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; EMERGENCY TREATMENT; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); ANALOGS AND DERIVATIVES; ANIMAL; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; HEMORRHAGE; HUMANS; MORPHOLINES; THIOPHENES; WARFARIN;

EID: 84888101914     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1270     Document Type: Review

References (90)

1. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC,. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5: 615-21.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 12: 1139-51.
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 10: 883-91.
4. Kelly JG, O'Malley K,. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979; 1: 1-15.
5. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 2: 386-99.
6. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 5: 555-63.
7. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M,. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 12: 873-80.
8. Lang D, Freudenberger C, Weinz C,. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 2009; 5: 1046-55.
9. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G,. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 2 (Suppl): e44S-88S.
10. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 3: 292-303.
11. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 6974: 537-41.
12. Friedman PA, Rosenberg RD, Hauschka PV, Fitz-James A,. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 1977; 1: 271-6.
13. Whitlon DS, Sadowski JA, Suttie JW,. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 8: 1371-7.
14. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N,. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 1: 155-62.
15. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
16. Vang ML, Hvas AM, Ravn HB,. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand 2011; 5: 507-16.
17. Nelsestuen GL, Zytkovicz TH, Howard JB,. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 19: 6347-50.
18. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 9241: 1551-3.
19. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D,. Comparison of oral versus intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 20: 2469-73.
20. Patriquin C, Crowther M,. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol 2011; 6: 657-67.
21. Hung A, Singh S, Tait RC,. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol 2000; 3: 537-9.
22. Fiore LD, Scola MA, Cantillon CE, Brophy MT,. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 2: 175-83.
23. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 4: 251-4.
24. Raj G, Kumar R, McKinney WP,. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999; 22: 2721-4.
25. Libby EN, Garcia DA,. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002; 16: 1893-6.
26. Bechtel BF, Nunez TC, Lyon JA, Cotton BA, Barrett TW,. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med 2011; 1: 40.
27. Demeyere R, Gillardin S, Arnout J, Strengers PF,. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 3: 251-60.
28. Zareh M, Davis A, Henderson S,. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med 2011; 4: 386-92.
29. Frazee LA, Bourguet CC, Gutierrez W, Elder-Arrington J, Elackattu AE, Haller NA,. Retrospective evaluation of a method to predict fresh-frozen plasma dosage in anticoagulated patients. Am J Ther 2008; 2: 111-8.
30. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 1: 82-92.
31. Schulman S, Bijsterveld NR,. Anticoagulants and their reversal. Transfus Med Rev 2007; 1: 37-48.
32. Fredriksson K, Norrving B, Stromblad LG,. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 7: 972-7.
33. Boulis NM, Bobek MP, Schmaier A, Hoff JT,. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 5: 1113-8; discussion 18-9.
34. Cartmill M, Dolan G, Byrne JL, Byrne PO,. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 5: 458-61.
35. Goodnough LT, Shander A,. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 23: 6091-9.
36. Franchini M, Lippi G,. Prothrombin complex concentrates: an update. Blood Transfus 2010; 3: 149-54.
37. Anonymous. Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther 2011; 1374: 78-9.
38. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B,. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 2: 137-43.
39. Bauer KA,. Reversal of antithrombotic agents. Am J Hematol 2012; 87: S119-26.
40. Baggs JH, Patanwala AE, Williams EM, Erstad BL,. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal. Ann Pharmacother 2012; 1: 51-6.
41. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R,. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 6: 1171-7.
42. Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE,. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg 2012; 3: 491-7.
43. Imberti D, Barillari G, Biasioli C, et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011; 2: 148-55.
44. Butenas S, Brummel KE, Bouchard BA, Mann KG,. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 6: 1158-60.
45. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 2 (Suppl): e152S-84S.
46. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 1 (Suppl): 8S-21S.
47. Hylek EM, Skates SJ, Sheehan MA, Singer DE,. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 8: 540-6.
48. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 4: 409-16.
49. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH,. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 11: 970-9.
50. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 7: 967-73.
51. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ,. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 5: 1515-22.
52. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 6 (Suppl): 160S-98S.
53. Duong TM, Plowman BK, Morreale AP, Janetzky K,. Retrospective and prospective analyses of the treatment of overanticoagulated patients. Pharmacotherapy 1998; 6: 1264-70.
54. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE,. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 11: 1612-7.
55. Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF,. Warfarin dose reduction versus watchful waiting for mild elevations in the international normalized ratio. Chest 2003; 2: 499-503.
56. White RH, McKittrick T, Hutchinson R, Twitchell J,. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 1: 40-2.
57. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 5: 293-300.
58. Crowther MA, Garcia D, Ageno W, et al. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost 2010; 1: 118-21.
59. Gunther KE, Conway G, Leibach L, Crowther MA,. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res 2004; 113: 205-9.
60. Yiu KH, Siu CW, Jim MH, et al. Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol 2006; 3: 409-11.
61. Ozgonenel B, O'Malley B, Krishen P, Eisenbrey AB,. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007; 12: 1091-4.
62. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF,. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 3: 477-80.
63. Deveras RA, Kessler CM,. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 11: 884-8.
64. Lin J, Hanigan WC, Tarantino M, Wang J,. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 4: 737-40.
65. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 12: 1495-500.
66. Van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006; 3: 313-20.
67. Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA,. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother 2011; 45: 869-75.
68. Tran H, Collecutt M, Whitehead S, Salem HH,. Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation. Intern Med J 2011; 4: 337-43.
69. Barillari G, Pasca S, Barillari A, De Angelis V,. Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. Blood Transfus 2012; 1: 87-94.
70. Sconce EA, Kamali F,. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol 2006; 6: 457-62.
71. Limdi NA, Acton RT, Beasely TM, Adler B,. The influence of CYP2C9 and VKORC1 1173C/T genotype on reversal of anticoagulation (INR) following phytonadione administration [abstract]. Blood 2007; 110: 3135.
72. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ,. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 6: 393-400.
73. Sconce EA, Avery PJ, Wynne HA, Kamali F,. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost 2008; 7: 1226-8.
74. Briz M, Talks K, Hanley J, et al. Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study. J Thromb Haemost 2010; 5: 1123-5.
75. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87: S141-5.
76. Crowther MA, Warkentin TE,. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009; 7: 107-10.
77. Kazmi RS, Lwaleed BA,. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 2011; 4: 593-603.
78. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 6: 1116-27.
79. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 4: 815-25.
80. Stangier J, Rathgen K, Stahle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 4: 259-68.
81. Stangier J, Stahle H, Rathgen K, Fuhr R,. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 1: 47-59.
82. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D,. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 5: 1056-64.
83. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010; 5: 703-12.
84. Garber ST, Sivakumar W, Schmidt RH,. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 2012; 116: 1093-6.
85. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J,. Epidural hematoma & intra-operative hemorrhage in a spine trauma patient on Pradaxa(R) [dabigatran]. Spine 2012; 37: E863-5.
86. Wychowski MK, Kouides PA,. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 4: e10.
87. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW,. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 9: 2172-4.
88. Cano EL, Miyares MA,. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012; 2: 160-3.
89. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 14: 1573-9.
90. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G,. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 2: 217-24.